期刊文献+

环氧合酶2基因沉默诱导人肝癌细胞凋亡的作用观察 被引量:6

Cyclooxygenase-2 gene silence induces apoptosis of human hepatocellular carcinoma cells
下载PDF
导出
摘要 目的观察作用于环氧合酶2(COX-2)mRNA的发卡状COX-2(COX-2 shRNA)真核表达质粒对人肝癌HepG2细胞增殖和凋亡的影响。方法设计靶向COX-2基因的RNA干扰序列,构建COX-2 shRNA表达载体,用阳离子脂质体Lipofectamine 2000转染体外培养的HepG2细胞。半定量RT-PCR检测COX-2 mRNA表达水平的变化,筛选有效抑制COX-2基因表达的序列。采用CCK-8细胞计数法检测COX-2 shRNA对细胞增殖的影响,流式细胞仪测定细胞凋亡率和细胞周期,Western blotting检测细胞内COX-2和Bcl-2蛋白表达水平。结果测序结果显示成功构建了2个表达COX-2 shRNA的质粒载体,转染HepG2细胞后COX-2 mRNA表达下降至阴性对照组的41.66%和77.79%。选择沉默效率较佳者转染细胞并经G418筛选,获得稳定表达COX-2 shRNA的细胞,胞内COX-2 mRNA表达水平下降了75.30%,细胞增殖活性下降了29.33%。在稳定表达COX-2 shRNA、错义序列以及未转染的细胞中,细胞凋亡率分别为17.83%、4.63%和4.47%,G0/G1期细胞比例分别为73.93%、61.2%和57.630%,而S期细胞比例分别为13.43%、26.03%和26.90%。Western blotting检测显示,表达COX-2 shRNA的HepG2细胞内COX-2蛋白水平下降至表达错义序列组的31.25%(P<0.01),Bcl-2蛋白水平下降至表达错义序列组的54.93%(P<0.01),而转染错义质粒组与未转染组之间比较差异无统计学意义。结论构建的真核表达载体pSilencer 2.1-U6-COX-2 shRNA能有效沉默人肝癌HepG2细胞内COX-2基因的表达,并具有抑制细胞增殖、促进细胞凋亡和细胞周期阻滞、降低胞内抗凋亡蛋白Bcl-2水平的作用。 Objective To specifically silence COX-2 gene expression in cultured human hepatocellular carcinoma cells HepG2 by construction and transfection of COX-2 hairpin RNA(shRNA) expression vectors,and investigate the effects of knocking off COX-2 on cell proliferation and apoptosis.Methods The inserted sequences coding shRNA homologous to COX-2 gene were designed and COX-2 shRNA expression vectors were constructed and transfected into HepG2 cells with Lipofectamine 2000.The inhibitory efficiency of COX-2 shRNA was determined by detection of COX-2 mRNA levels in transfected cells using semi-quantitative RT-PCR.Cell viability was analyzed by cell counting kit-8(CCK-8) assay.Indexes of apoptotic cells and cell cycle distribution were analyzed by flow cytometry.Western blotting was used to detect the changes in protein levels of COX-2 and Bcl-2 in HepG2 cells.Results Plasmid sequencing showed the successful construction of two shRNA expression vectors.The expressive levels of COX-2 mRNA in HepG2 cells transfected with two COX-2 shRNA expression vectors decreased to 41.66% and 77.79%,respectively,of that in cells transfected with control scrambled shRNA expression vector.The vector which efficiently suppressed the expression of COX-2 mRNA was transfected into HepG2 cells,and G418 was used to select a population of cells which may stably express the shRNA.The expression of COX-2 mRNA decreased by 75.30% and the cell viability decreased by 29.33% in cells which stably expressed COX-2 shRNA.Flow cytometry analysis showed a higher proportion of apoptotic cells in COX-2 shRNA group than in untransfected and scrambled shRNA groups(17.83% vs 4.47% and 4.63%).The proportion of cells in G0/G1 phase was 73.93%,57.63% and 61.2%,while in S phase was 13.43%,26.90% and 26.03%,respectively,in COX-2 shRNA group,untransfected and scrambled shRNA groups.Western blotting revealed that the protein levels of COX-2 and Bcl-2 in HepG2 cells which expressed COX-2 shRNA reduced to 31.25%(P0.01) and 54.93%(P0.01) of scrambled shRNA expression vector respectively.Conclusion Recombinant expression vector pSilencer 2.1-U6-COX-2 shRNA may efficiently silence COX-2 gene expression,inhibit cell proliferation,promote apoptosis,arrest cell cycle and decrease the Bcl-2 protein level in human hepatocellular carcinoma cells HepG2.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2012年第7期715-719,共5页 Medical Journal of Chinese People's Liberation Army
基金 广东省自然科学基金(S2011010003787) 广东省科技计划项目(2011B031800128) 广州市科技计划重点项目(11C32120715)~~
关键词 环氧化酶2 SHRNA 肝细胞 细胞凋亡 BCL-2相关X蛋白质 cyclooxygenase 2 shRNA carcinoma hepatocellular apoptosis bcl-2-associated X pr
  • 相关文献

参考文献10

  • 1Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 andcancer treatment: understanding the risk should be worth the reward[J]. Clin Cancer Res, 2010, 16(5): 1384-1390.
  • 2Schmitz KJ, Wohlschlaeger J, Lang H, et al. Cyclooxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis[J]. J Clin Pathol, 2009, 62(8): 690-693.
  • 3Morinaga S, Yamamoto Y, Noguchi Y- et al. Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2002, 17(10): 1110-1116.
  • 4Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398[J]. Clin Cancer Res, 2001, 7(5): 1410-1418.
  • 5Cheng J, Imanishi H, Amuro Y, et al. NS-398, a selective cyclooxygenase-2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines[J]. IntJ Cancer, 2002, 99(5): 755-761.
  • 6Park MK, Hwang SY, Kim JO, et al. NS398 inhibits the growth of Hep3B human hepatocellular cells via caspase-independent apoptosis [J]. Mol Cells, 2004, 17(1): 45-50.
  • 7ParkJH, Kang KH, Kim SH, et al. Expression of cyclooxygenase-2 and Bcl-2 in human gastric adenomas[J]. Korean J Intern Med, 2005, 20(3): 198-204.
  • 8Krysan K, Dalwadi H, Sharma S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non- small cell lung cancer[J]. Cancer Res, 2004, 64(18): 63S9-6362.
  • 9Lee NO, Park JW, Lee JA, et al. Dual action of a selective cyclooxygenase-2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: novel involvement of discoidin domain receptor 2[J]. J Cancer Res Clin Oncol, 2012, 138(1): 73-84.
  • 10Cheng AS, Yu J, Lai PB, et al. COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis[J]. Biochem Biophs Kes Commun, 2008, 374(2): 175-180.

同被引文献59

  • 1TerenceC.Tang,RonnieT.Poon,CeciliaP.Lau,Danxie,SheungTatFan.Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(13):1896-1902. 被引量:37
  • 2陈琦晗,徐仑,季正华,丁云芳,朱宏.重组人活化蛋白C对大鼠急性胃黏膜损伤的保护作用[J].中国小儿急救医学,2006,13(6):543-546. 被引量:1
  • 3汤钊猷.现代肿瘤学[M].2 版.上海:上海医科大学出版社,2001:553.
  • 4Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays [J]. J Immunol Methods, 1983, 65(1/2) :55.
  • 5黄世泰,周有恒.肝舒注射液治疗肝炎疗效观察[J].中成药研究,1979(3):34.
  • 6RienerMO, Stenner F, L iewen H, et al. Golgi phosphopro- tein 2(GOLPH 2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas[J]. Hepatology, 2009, 49(5):1602-1609.
  • 7Li X, Wu K, Fan D. Serum golgi phosphoprotein 2 level: a better marker than alpha fetoprotein for diagnosing eariy hepatocellular carcinoma[J]. Hepatology, 2009, 50(5):1652.
  • 8Buvanendran A, Kroin JS, Berger RA, et al. Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans[J].Anesthesiology, 2006, 104(3): 403-410.
  • 9Kawashima M, Ogura N, Akutsu M, et al. The anti-inflammatory effect of cyclooxygenase inhibitors in fibroblast-like synoviocytes from the human temporomandibular joint results from the suppression of PGE2 production[J]. J Oral Pathol Med, 2013, 42(6): 499-506.
  • 10Robert A, Nezamis JE, Lancaster C, et al. Cytoprotection prostaglands exogenous or endogenous can maintain gastric secretory function[J]. Gastroenterology, 1978, 74: 1086.

引证文献6

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部